Tumor lysis syndrome in multiple myeloma treated with bortezomib
نویسندگان
چکیده
منابع مشابه
Bortezomib-induced tumor lysis syndrome in multiple myeloma.
Tumor lysis syndrome (TLS) is exceedingly rare in multiple myeloma because of the relatively slow proliferation and response of the malignant cells. Bortezomib is a novel agent that inhibits proteasome and has shown activity against multiple myeloma. We report 8 episodes of TLS seen in 7 patients with bortezomib therapy, with or without dexamethasone, among 496 patients treated on 3 phase II mu...
متن کاملTumor lysis syndrome in a multiple myeloma treated with thalidomide.
A 60-year-old male with progressive high burden non-secretory multiple myeloma (NSMM) presented with tumor lysis syndrome (TLS) after starting thalidomide. He was diagnosed in 1998 with NSMM stage IIIA according to Durie and Salmon’s classification. Initial treatment consisted of six cycles of vincristine, doxorubicin and dexamethasone (VAD), and double high doses of melphalan supported by auto...
متن کاملHigh Risk of Tumor Lysis Syndrome in Symptomatic Patients with Multiple Myeloma with Renal Dysfunction Treated with Bortezomib.
BACKGROUND/AIM Tumor lysis syndrome (TLS) is a life-threatening complication associated with cancer chemotherapy. We retrospectively evaluated the risk of developing TLS in patients with symptomatic multiple myeloma undergoing chemotherapy. PATIENTS AND METHODS Sixty-four patients (median age=71 years, range=48-87 years, 35 males/29 females) who were treated at our Institution between April 2...
متن کاملManagement of tumor lysis syndrome in patients with multiple myeloma during bortezomib treatment.
BACKGROUND Tumor lysis syndrome (TLS) is a severe, life-threatening complication that typically occurs in highly proliferative malignancies. Although TLS is unusual in multiple myeloma (MM), it is still associated with significant morbidity. Bortezomib has been widely used for the treatment of MM with encouraging results, but TLS seems to occur more frequently in patients with MM receiving bort...
متن کاملTumor lysis syndrome in patients with light chain multiple myeloma: report of two cases.
Tumor lysis syndrome (TLS) is a severe life-threatening complication which typically occurs in highly proliferative malignancies, such as Burkitt's lymphoma, acute leukemia or germ cell tumors. Although TLS is unusual in multiple myeloma, it should not be overlooked as it is associated with significant morbidity. In recent years, emerging new agents such as thalidomide and bortezomib have been ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Pharmacology and Pharmacotherapeutics
سال: 2014
ISSN: 0976-500X
DOI: 10.4103/0976-500x.130091